Comparing Three Treatment Approaches for Children and Adolescents With Juvenile Idiopathic Arthritis in Remission The MOVE-JIA Trial

What this Trial Is About

Researchers are comparing three different treatment strategies for children and adolescents with juvenile idiopathic arthritis JIA who are in sustained remission. The study aims to find out if the rate of disease flare differs between continuing stable treatment and two types of drug withdrawal over 12 months. It also looks at the timing of flare occurrence and how long it takes to regain remission after a flare. Participants will be randomly assigned to one of three groups continued stable treatment with methotrexate and a tumor necrosis factor inhibitor TNFi, gradual withdrawal of methotrexate while maintaining TNFi, or gradual withdrawal of TNFi. The study involves regular visits every 4 months, with extra visits if symptoms suggest a flare. If a flare occurs, the original medications will be restarted. During the study, participants will undergo assessments every 4 months, including evaluations of disease activity by joint counts and physician global assessments. Laboratory tests such as erythrocyte sedimentation rate ESR and C-reactive protein CRP levels will be measured. Patient or parent assessments of well-being and monitoring for adverse events will also be conducted. The study lasts for at least 12 months of follow-up to track flares, disease activity, and safety.

Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial